Hyphens Pharma gets exclusive rights to distribute European autoinjector

It will distributed in Singapore, Malaysia, the Philippines, and Vietnam.

Hyphens Pharma International Limited’s subsidiary, Hyphens Pharma, has obtained an exclusive right to market subcutaneous autoinjector Metoject pen.

Hyphens Pharma signed an agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to distribute in Singapore, Malaysia, the Philippines, and Vietnam for rheumatoid arthritis treatment.

Metoject may also be used for the treatment of plaque psoriasis and has a lower intensity of certain gastrointestinal side effects compared to the oral drug.

The autoinjector pen’s design ensures simple two-step self-injection with an enhanced safety feature of a built-in needle and is available in multiple strengths including 7.5mg, 10mg, and 15mg.

Reaching the people who run Asia's businesses is harder than it used to be.

Inboxes are crowded. Attention is short. The executives you most want to reach — the founders, CFOs, and operators who actually move budgets — are the hardest to find through the usual channels. If you're building a company, a category, or a reputation, you already know this.

We've spent twenty years building the room they read. Singapore Business Review is where senior decision makers in Singapore and across Southeast Asia come for business coverage they can't get elsewhere — in print, online, and in person at the summits and roundtables we host across seven markets.

If you have something these readers should know about — a point of view worth publishing, a product worth their attention, an event worth their time — we'd like to hear what you're trying to do.

Book a meeting

| Or download the media kit (PDF)

240,000 senior readers quarterly in print Top 1,700 Singapore companies reached

7 markets across Southeast Asia